Study S001759

A Single-Center, Open-Label, Single Ascending Dose Study to Evaluate the Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of Exenatide Circular RNA-Lipid Nanoparticle Injection (CR059) in Chinese Subjects With Type 2 Diabetes Mellitus

ClinicalTrials.gov record

Registration

Registration: NCT07347080
Acronym: CR059101
Study type: INTERVENTIONAL
Phase: EARLY_PHASE1
Masking: NONE
Status: RECRUITING
Enrollment: 9
Start: 2026-01-20
Primary completion: 2026-08-31
Lead sponsor: The First Affiliated Hospital of Henan University of Science and Technology
Conditions: T2DM
Interventions: DRUG:Exenatide Circular RNA-Lipid Nanoparticle Injection（ CR059））
Results posted: FALSE
Individual participant data sharing: YES

Registered primary outcomes

Incidence of Treatment-Emergent Adverse Events (TEAEs) [From the first dosing (Day 1 ) of study drug until completion of the post treatment follow-up visit(Day 36)]

Linked records (0)

Automatic links, confirmed or rejected during screening. A record citing this registration may be a secondary analysis, a commentary or a review that mentions the trial.

No records link to this registration yet.